Ionis Pharmaceuticals and AstraZeneca failed a heart drug trial, leading to stock declines and market commentary.
4 reports, 4 independent
Updated Aug 6
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ionis Pharmaceuticals and AstraZeneca failed a heart drug trial, leading to stock declines and market commentary.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ionis Pharmaceuticals
American pharmaceutical company
Nothing else this week.
-
AstraZeneca
British-Swedish pharmaceutical company
Related events
- AstraZeneca listed shares on the New York Stock Exchange to attract investors.
- AstraZeneca sought a mega-merger with a US rival, adding a specific development to the ongoing talks with Bristol-Myers Squibb.
- AstraZeneca presented trial results at the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.